Loading
A phase 1/2 trial of Pembrolizumab in bladder & urothelial cancer, run by Merck Sharp & Dohme LLC, now recruiting.
KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04) is a phase 1/2 interventional study registered as NCT07232602 by Merck Sharp & Dohme LLC, with 55 participants planned, started 2026-02-09 and due to reach its primary completion in 2031-07-08. Interventions recorded: MK-3120, EV, Pembrolizumab and Rescue Medication.
Shares Muscle-invasive and advanced bladder cancer, Merck & Co. (MSD), Bladder & urothelial cancer, Pembrolizumab and the tag pipeline.
Shares Muscle-invasive and advanced bladder cancer, Merck & Co. (MSD), Bladder & urothelial cancer, Pembrolizumab and the tag pipeline.
Shares Muscle-invasive and advanced bladder cancer, Merck & Co. (MSD), Bladder & urothelial cancer, Pembrolizumab and the tag pipeline.
Shares Merck & Co. (MSD), Bladder & urothelial cancer, Pembrolizumab, Immune checkpoint inhibitors and the tag pipeline.
Shares Muscle-invasive and advanced bladder cancer, Merck & Co. (MSD), Bladder & urothelial cancer, Pembrolizumab and the tag pipeline.
Shares Muscle-invasive and advanced bladder cancer, Merck & Co. (MSD), Bladder & urothelial cancer, Pembrolizumab and the tag pipeline.
Shares Muscle-invasive and advanced bladder cancer, Merck & Co. (MSD), Bladder & urothelial cancer, Pembrolizumab and the tag pipeline.
Shares Merck & Co. (MSD), Pembrolizumab, Immune checkpoint inhibitors and the tag pipeline.